Puma biotechnology director Troy Wilson sells $77,748 of stock

Prior to these sales, on June 11, 2026, Mr. Wilson acquired 27,000 shares of common stock. These shares represent Restricted Stock Units (RSUs) that vest in full on the earlier of the one-year anniversary of the grant date or the date of the annual shareholder meeting following the grant date, contingent on Mr. Wilson’s continued service with Puma Biotechnology.

Following these transactions, Mr. Wilson directly holds 59,750 shares of Puma Biotechnology common stock. Additionally, he indirectly holds 400 shares through Child #1 and 150 shares through Child #2.

In other recent news, Puma Biotechnology Inc. reported its first-quarter 2026 earnings, which fell short of analyst expectations. The company posted an earnings per share (EPS) of -$0.04, missing the forecasted EPS of $0.00. Additionally, Puma Biotech’s revenue for the quarter was $44.8 million, below the anticipated $49 million, resulting in a revenue surprise of -8.57%. These earnings results indicate a challenging quarter for the company as both earnings and revenue figures were below projections. There was no mention of any mergers or acquisitions in the recent updates. Analyst firms have not provided any new upgrades or downgrades for Puma Biotech in this period. These recent developments provide a snapshot of the company’s current financial standing.